In xenograft models, rosiglitazone treatment resulted in a marked reduction in tumor volume, decreased microvessel density, and increased expression of C-X-C motif chemokine ligand 12 (CXCL12), a signaling protein associated with lower malignancy and better survival (56). The gene discussed is CXCL12; the disease is neoplasm.